Is Stiripentol currently officially on the market in China?

Stiripentol has not yet been officially launched in China and has not been included in the medical insurance system. This information is crucial to many families of epilepsy patients who need to use the drug, especially rare epilepsy types such as Dravet syndrome. Since the disease often appears in infancy and early childhood, treatment options are limited, so the progress of the drug's launch has attracted much attention.

As an important innovative drug in the field of anti-epilepsy, stiripentol was first approved in Europe and has since been used as the main treatment for refractory epilepsy in the United States, Canada, Japan and other countries. Global clinical use experience has gradually accumulated, confirming its important value in reducing the frequency of epileptic seizures and improving the quality of life of patients. However, in the Chinese market, the drug is still in the pre-introduction stage due to factors such as patents, drug review processes, and the need for localization of clinical data.

Although it is not yet on the market, some domestic medical institutions may obtain the drug through special imports or clinical research projects for the treatment of specific patients. However, this does not fall within the scope of state-approved marketing, and the costs are usually not reimbursable through medical insurance. The prices of overseas original drugs are relatively high, which puts a certain amount of financial pressure on families. This is also one of the reasons why drugs have not been introduced into the domestic market on a large scale.

From the perspective of policy trends, the domestic review process for rare disease drugs and children's drugs has been accelerating in recent years. Stipentol is a typical rare disease drug and has great market potential in the future. Once approved, it is expected to complement the currently available anti-epileptic drugs in China and improve the treatment of refractory epilepsy.

Before the drugs are on the market, if patients urgently need such drugs, they should evaluate whether they are suitable for applying for overseas drug acquisition methods through formal channels under the guidance of professional doctors, and avoid purchasing from informal sources to avoid unknown drug sources and quality risks.

Reference materials:https://www.diacomit.com/